DK200500170A - Præparat, fremgangsmåde og kit til påvisning af antistoffer mod et humant retrovirus in vitro - Google Patents

Præparat, fremgangsmåde og kit til påvisning af antistoffer mod et humant retrovirus in vitro Download PDF

Info

Publication number
DK200500170A
DK200500170A DK200500170A DKPA200500170A DK200500170A DK 200500170 A DK200500170 A DK 200500170A DK 200500170 A DK200500170 A DK 200500170A DK PA200500170 A DKPA200500170 A DK PA200500170A DK 200500170 A DK200500170 A DK 200500170A
Authority
DK
Denmark
Prior art keywords
hiv
vitro
antibodies
composition
human
Prior art date
Application number
DK200500170A
Other languages
English (en)
Inventor
Montagnier Luc
Chamaret Solange
Guetard Denise
Alizon Marc
Clavel Francois
Guyader Mireille
Sonigo Pierre
Brun-Vezinet Francoise
Rey Marianne
Rouzioux Christine
Katlama Christine
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27576220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200500170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8600910A external-priority patent/FR2593189B1/fr
Priority claimed from FR8600911A external-priority patent/FR2593190B1/fr
Priority claimed from FR8601635A external-priority patent/FR2593922B1/fr
Priority claimed from FR8601985A external-priority patent/FR2594229B1/fr
Priority claimed from US06/835,228 external-priority patent/US4839288A/en
Priority claimed from FR8603881A external-priority patent/FR2596063B1/fr
Priority claimed from FR8604215A external-priority patent/FR2597500B1/fr
Publication of DK200500170A publication Critical patent/DK200500170A/da
Priority to DK200500170A priority Critical patent/DK176253B1/da
Application filed by Pasteur Institut filed Critical Pasteur Institut
Priority to DK200600325A priority patent/DK200600325A/da
Publication of DK176253B1 publication Critical patent/DK176253B1/da
Application granted granted Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Description

Patentkrav 1. Præparat tif in vitro påvisning af tilstedeværelsen i en biologisk prøve af antistoffer mod et humant retrovirus, der er i stand til at have cytopatogen virkning på humane T4 lymfocytter, omfattende mindst et HIV-1 antigen, kendetegnet ved, at det yderligere omfatter mindst et HIV-2 antigen der genkendes af antistofferne, der fremkaldes mod de tilsvarende antigener af et vilkårligt af de i CNCM deponerede HIV-2 retrovirus med numrene I- 502, I-532, I-642 og I-643 eller i ECACC deponerede HIV-2 retrovirus med numrene 87.011001 og 87.011002 {svarende til henholdsvis I-502 og I-532) eller en variant af en af disse HIV-2 retrovirus, 2. Præparat ifølge krav 1,kendetegnet ved, at det omfatter et gly¬ coprotein af HIV-2 retrovirus. 3. Præparat ifølge krav 1, kendetegnet ved, at det omfatter et HIV-2 p12 protein, der genkendes immunologisk af antistoffer fremkaldt mod de deponerede HIV-2 retrovira og har en molekylvægt i størrelsesordenen 12.000 daltons. 4. Præparat ifølge ethvert af kravene 1 til 3, kendetegnet ved, at det omfatter kerneproteiner fra HIV-1 og fra HIV-2. 5. Præparat ifølge krav 4, kendetegnet ved, at det omfatter p25 fra HIV-1 og p26 fra HIV-2. 6. Præparat ifølge krav 4, kendetegnet ved, at det omfatter p18 fra HIV-1 og p16 fra HIV-2. 7. Præparat ifølge krav 1,kendetegnet ved, at det inde omfatter holder omhylningsglycoproteiner fra HIV-1 og omhylningsglycoproteiner fra HIV-2. 8. Præparat ifølge krav 7, kendetegnet ved, at det omfatter gp110 fra HIV-1 og gp140 fra HIV-2. 9. Præparat ifølge krav 7 eller 8, kendetegnet ved, at det omfatter p42 fra HIV-1 og p36 fra HIV-2. 10. Præparat ifølge krav 1,kendetegnet ved, at det indeholder blan¬ dinger af antigeniske proteiner og/eller glycoproteiner fra HIV-1, og/eller blandinger af proteiner og/eller glycoproteiner fra HIV-2. 11. Fremgangsmåde til in vitro påvisning i en human biologisk prøve, f.eks. et serum, af tilstedeværelsen af antistoffer, der genkender antigener fra et hu¬ mant retrovirus, der er i stand til at have cytopatogen virkning på de humane T4 lymfocyter, og specielt til in vitro diagnose af en potentiel eller eksisteren¬ de LAS eller AIDS, der er forårsaget af et humant retrovirus, kendetegn e t ved, at man bringer den biologiske prøve fra den person, der skal diag¬ nosticeres, i kontakt med en blanding af antigener, der er i stand til at give en specifik immunologisk reaktion med antistofferne mod et humant HIV-1 retro¬ virus, eller mod et humant HIV-2 retrovirus, der er i stand til at have en cytopatogen virkning, og som genkendes af antistofferne, der fremkaldes mod de tilsvarende antigener af et vilkårligt af de i CNCM deponerede HIV-2 retrovirus med numrene I-502, I-532, I-642 og I-643 eller i ECACC depone¬ rede HIV-2 retrovirus med numrene 87.011001 og 87.011002 (svarende til henholdsvis I-502 og I-532), eller en variant af en af disse HIV-2 retrovira, og at man påviser et muligt dannet immunologisk konjugat mellem mindst et af disse antigener og antistofferne. 12. Fremgangsmåde ifølge krav 11,kendetegnet ved, at man bringer den biologiske prøve fra den person, som skal diagnosticeres, i kontakt med en blanding af antigener fra både et HIV-1 og et HIV-2 retrovirus, hvilket anti- gen fra HIV-2 genkendes af antistofferne, der fremkaldes mod de tilsvarende antigener af et vilkårligt af de i CNCM deponerede HIV-2 retrovirus med num¬ rene 1-502, 1-532, 1-642 og 1-643 eller i ECACC deponerede HIV-2 retrovirus med numrene 87.011001 og 87.011002 (svarende til henholdsvis I-502 og I- 532) eller en variant af en af disse HIV-2 retrovirus, specielt med et præparat ifølge et vilkårligt af kravene 1-8, og at man påviser det muligt dannede im¬ munologiske konjugat mellem mindst et af disse antigener og antistofferne. 13. Kit til in vitro påvisning af tilstedeværelse af antistoffer mod et retrovirus, der er cytopatogent for humane T4 lymfocyter, specielt hos en person, der muligvis bærer disse antistoffer, kendetegnet ved, at det omfatter en blanding af mindst et HIV-1 antigen og mindst et HIV-2 antigen, specielt et præparat som defineret i et vilkårligt af kravene 1-8; midler til påvisning af et immunologisk konjugat, der resulterer af den immunologiske reaktion mellem antigenerne og antistofferne i den biologiske væske.
DK200500170A 1986-01-22 2005-02-04 Præparat, fremgangsmåde og kit til påvisning af antistoffer mod et humant retrovirus in vitro DK176253B1 (da)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DK200500170A DK176253B1 (da) 1986-01-22 2005-02-04 Præparat, fremgangsmåde og kit til påvisning af antistoffer mod et humant retrovirus in vitro
DK200600325A DK200600325A (da) 1986-01-22 2006-03-06 Fremgangsmåde til in vitro detektion af en HIV-2 retrovirus

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
FR8600910A FR2593189B1 (fr) 1986-01-22 1986-01-22 Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
FR8600910 1986-01-22
FR8600911 1986-01-22
FR8600911A FR2593190B1 (fr) 1986-01-22 1986-01-22 Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
FR8601635A FR2593922B1 (fr) 1986-02-06 1986-02-06 Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
FR8601635 1986-02-06
FR8601985A FR2594229B1 (fr) 1986-02-13 1986-02-13 Nouveau retrovirus du type lav-ii susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
FR8601985 1986-02-13
US83522886 1986-03-03
US06/835,228 US4839288A (en) 1986-01-22 1986-03-03 Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
FR8603881A FR2596063B1 (fr) 1986-03-18 1986-03-18 Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
FR8603881 1986-03-18
FR8604215A FR2597500B1 (fr) 1986-03-24 1986-03-24 Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
FR8604215 1986-03-24
US91608086A 1986-10-06 1986-10-06
US91608086 1986-10-06
US93318486A 1986-11-21 1986-11-21
US93318486 1986-11-21
DK198704934A DK175959B1 (da) 1986-01-22 1987-09-21 Human HIV-2 retrovirus, der kan fremkalde AIDS, samt fremgangsmåde og middel til påvisning af dettte retrovirus in vitro
DK493487 1987-09-21
DK200500170A DK176253B1 (da) 1986-01-22 2005-02-04 Præparat, fremgangsmåde og kit til påvisning af antistoffer mod et humant retrovirus in vitro
DK200500170 2005-02-04

Publications (2)

Publication Number Publication Date
DK200500170A true DK200500170A (da) 2005-02-04
DK176253B1 DK176253B1 (da) 2007-04-30

Family

ID=27576220

Family Applications (2)

Application Number Title Priority Date Filing Date
DK198704934A DK175959B1 (da) 1986-01-22 1987-09-21 Human HIV-2 retrovirus, der kan fremkalde AIDS, samt fremgangsmåde og middel til påvisning af dettte retrovirus in vitro
DK200500170A DK176253B1 (da) 1986-01-22 2005-02-04 Præparat, fremgangsmåde og kit til påvisning af antistoffer mod et humant retrovirus in vitro

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK198704934A DK175959B1 (da) 1986-01-22 1987-09-21 Human HIV-2 retrovirus, der kan fremkalde AIDS, samt fremgangsmåde og middel til påvisning af dettte retrovirus in vitro

Country Status (15)

Country Link
EP (2) EP0320495B1 (da)
JP (7) JP2611106B2 (da)
AR (1) AR243931A1 (da)
AT (2) ATE47725T1 (da)
AU (1) AU601397B2 (da)
DE (3) DE3760912D1 (da)
DK (2) DK175959B1 (da)
ES (1) ES2150897T3 (da)
GR (3) GR880300056T1 (da)
HK (1) HK62091A (da)
NZ (1) NZ219024A (da)
OA (1) OA08468A (da)
PT (1) PT84182B (da)
SG (1) SG28591G (da)
WO (1) WO1987004459A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249611A4 (en) * 1985-11-14 1988-04-26 Harvard College T-LYMPHOTROPHIC VIRUS.
EP0750041B1 (fr) * 1987-01-16 2008-12-10 Institut Pasteur Séquences de nucléotides de HIV-2 et SIV-1
DE3855947T2 (de) * 1987-01-16 1997-12-11 Pasteur Institut Peptide mit den immunologischen Eigenschaften von HIV-2
AU620804B2 (en) * 1987-03-23 1992-02-27 Hiver Limited Novel vaccines
SE8701765L (sv) * 1987-04-28 1988-10-29 Statens Bakteriologiska Lab Analysmetod och medel foer denna
US4812556A (en) * 1987-05-18 1989-03-14 Virovahl Synthetic peptide antigen for the detection of HIV-2 infection
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
US5780038A (en) * 1987-11-16 1998-07-14 Roche Diagnostic Systems, Inc. HIV-2 envelope polypeptides
ATE87487T1 (de) * 1987-11-16 1993-04-15 Hoffmann La Roche Rekombinante hiv-2 polypeptide.
WO1989006276A2 (en) * 1988-01-08 1989-07-13 Dpz Deutsches Primatenzentrum Gesellschaft Mbh Hiv-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
US6210874B1 (en) 1988-01-27 2001-04-03 Biochem Immunosystems, Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
WO1989009815A1 (en) * 1988-04-04 1989-10-19 Research Corporation Technologies, Inc. Novel virus of the hiv-2 family and methods of detection therefor
US6197496B1 (en) 1988-06-09 2001-03-06 Institut Pasteur Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins gp300, p200, and p90/80
EP1369427A3 (en) * 1988-06-09 2004-05-12 Innogenetics N.V. HIV-3 retrovirus strains and their use
US5208321A (en) 1988-06-09 1993-05-04 Institut Pasteur HIV-2 transmembrane glycoprotein homodimer (GP 80)
EP0345559A3 (en) * 1988-06-10 1990-07-11 Abbott Laboratories Hiv-2 variants
DE68927025T2 (de) † 1988-06-14 1997-03-27 Qiagen Gmbh HIV-2-Virusvarianten
ATE136789T1 (de) * 1989-05-12 1996-05-15 Pasteur Institut Antigene eines transmembranen hüllenglycoproteins eines menschlichen retrovirus des typs hiv-2 und immunologisch verwandte antigene
FR2646854A1 (fr) * 1989-05-12 1990-11-16 Pasteur Institut Antigenes de la glycoproteine transmembranaire d'enveloppe d'un retrovirus humain du type hiv-2 antigenes presentant avec eux une parente immunologique
DE68925202T2 (de) * 1989-05-31 1996-06-05 Pasteur Institut HIV-2-EHO-Retrovirus-Proteine und -Glycoproteine, Antikörper gegen sie, Verwendung für diagnostische Zwecke
ES2275451T3 (es) * 1989-06-02 2009-02-16 Institut Pasteur Secuencias nucleotidicas procedentes del genoma de los retrovirus del tipo vih-1,vih-2 y siv, y sus aplicaciones especialmente para la amplificacion de los genomas de estos retrovirus y para el diagnostico in vitro de las infecciones debidas a estos virus.
FR2647810B1 (fr) * 1989-06-02 1994-07-22 Pasteur Institut Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
FR2647809B1 (fr) * 1989-06-02 1991-09-20 Pasteur Institut Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
US7022814B1 (en) 1992-01-21 2006-04-04 Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
FR2657016B1 (fr) * 1990-01-16 1995-08-25 Clonatec Sa Peptides derivant de la glycoproteine d'enveloppe du virus-hiv-2, leurs applications a la detection d'une infection due a ce virus et a la vaccination contre le sida.
EP0438332B1 (fr) * 1990-01-16 1998-04-08 Orgenics Ltd. Peptides dérivant de la glycoprotéine d'enveloppe de virus HIV, leurs applications à la détection d'une infection due à ces virus et à la vaccination contre le SIDA
ATE105857T1 (de) 1990-06-15 1994-06-15 Innogenetics Nv Siv cpz-ant retrovirus und seine anwendungen.
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
CA2107732C (en) * 1992-10-06 2003-04-08 Lutz G. Gurtler Retrovirus from the hiv group and its use
DE4233646C2 (de) * 1992-10-06 2003-10-23 Dade Behring Marburg Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
US5962665A (en) * 1997-06-16 1999-10-05 Abbott Laboratories Nucleic acid primers and probes for detecting HIV-1 and HIV-2
FR2767337B1 (fr) 1997-08-14 2002-07-05 Pasteur Institut Sequences nucleiques de polypeptides exportes de mycobacteri es, vecteurs les comprenant et applications au diagnostic et a la prevention de la tuberculose
CA2422956C (en) 2000-10-23 2010-10-19 Gen-Probe Incorporated Compositions and methods for detecting human immunodeficiency virus 2 (hiv-2)
CA2547750C (en) 2003-12-19 2014-04-08 Gen-Probe Incorporated Compositions, methods and kits for detecting the nucleic acids of hiv-1 and hiv-2
JP6721772B1 (ja) 2019-03-26 2020-07-15 斉藤　幹雄 清掃装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652599A (en) * 1984-04-23 1987-03-24 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS using permissive cells
ATE250083T1 (de) * 1984-10-18 2003-10-15 Pasteur Institut Lav-antigene und -peptide
US4600413A (en) * 1984-12-10 1986-07-15 Sundstrand Corporation Centrifugal deaerator and pump
JP3105581B2 (ja) * 1991-07-03 2000-11-06 内橋エステック株式会社 面状温度ヒュ−ズ

Also Published As

Publication number Publication date
JP2771519B2 (ja) 1998-07-02
DE239425T1 (de) 1988-06-30
DK176253B1 (da) 2007-04-30
JP2931294B2 (ja) 1999-08-09
JP2735521B2 (ja) 1998-04-02
EP0239425A1 (fr) 1987-09-30
NZ219024A (en) 1990-04-26
ATE47725T1 (de) 1989-11-15
ES2150897T3 (es) 2000-12-16
PT84182A (pt) 1987-02-01
EP0239425B1 (fr) 1989-11-02
JPH0975092A (ja) 1997-03-25
GR880300056T1 (en) 1988-10-18
PT84182B (pt) 1989-09-14
DE3752319T2 (de) 2001-03-15
AU601397B2 (en) 1990-09-13
JP2801162B2 (ja) 1998-09-21
JPH08113598A (ja) 1996-05-07
AR243931A1 (es) 1993-09-30
DK175959B1 (da) 2005-08-29
JPH06113833A (ja) 1994-04-26
JPH0937778A (ja) 1997-02-10
GR3034708T3 (en) 2001-01-31
DE3752319D1 (de) 2000-09-07
AU6891187A (en) 1987-08-14
ATE195148T1 (de) 2000-08-15
DK493487A (da) 1987-11-17
DE3760912D1 (en) 1989-12-07
HK62091A (en) 1991-08-16
EP0320495A1 (fr) 1989-06-14
OA08468A (fr) 1988-07-29
JPH1118768A (ja) 1999-01-26
JPH08275783A (ja) 1996-10-22
WO1987004459A1 (fr) 1987-07-30
JPH07233196A (ja) 1995-09-05
JP2874846B2 (ja) 1999-03-24
SG28591G (en) 1993-02-19
GR3001096T3 (en) 1992-04-17
JP2611106B2 (ja) 1997-05-21
DK493487D0 (da) 1987-09-21
EP0320495B1 (fr) 2000-08-02

Similar Documents

Publication Publication Date Title
DK200500170A (da) Præparat, fremgangsmåde og kit til påvisning af antistoffer mod et humant retrovirus in vitro
Salahuddin et al. HTLV-III in symptom-free seronegative persons
Hauser et al. Analysis of human T-lymphotropic virus sequences in multiple sclerosis tissue
EP0655501B2 (en) HIV-2 virus variants
Reiss et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV‐1
BRPI0210598B8 (pt) processos para a produção de um complexo solúvel que compreende uma proteína amiloidogênica alvo e uma chaperona peptidil-prolil-isomerase, para a produção de um complexo de glicoproteína retroviral de superfície-chaperona solúvel, e para detectar pelo menos um anticorpo para uma glicoproteína retroviral de superfície em uma amostra, bem como complexo solúvel, e composição
Archibald et al. Salivary antibodies as a means of detecting human T cell lymphotropic virus type III/lymphadenopathy-associated virus infection
Irwin et al. Presence of human immunodeficiency virus (HIV) type 1 subtype A infection in a New York community with high HIV prevalence: a sentinel site for monitoring HIV genetic diversity in North America
CN1954217B (zh) 衍生自gp41的多肽、含有所述多肽的疫苗组合物以及用于治疗个体HIV病毒感染的用途
Chou et al. Antibody responses in early human immunodeficiency virus type 1 infection in hemophiliacs
Schochetman et al. Serodiagnosis of infection with the AIDS virus and other human retroviruses
US5019510A (en) Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
ES2058259T3 (es) Antigenos sinteticos para la deteccion de enfermedad relacionada con sida causada por lav-2.
Närvänen et al. Synthetic env gp41 peptide as a sensitive and specific diagnostic reagent in different stages of human immunodeficiency virus type 1 infection
Kline et al. Evaluation of Chiron HIV-1/HIV-2 recombinant immunoblot assay
Pepose et al. Screening cornea donors for antibodies against human immunodeficiency virus: efficacy of ELISA testing of cadaveric sera and aqueous humor
Kline et al. Diagnosis and differentiation of HIV-1 and HIV-2 infection by two rapid assays in Nigeria
Bahraoui et al. Relevance of anti-nef antibody detection as an early serologic marker of human immunodeficiency virus infection
Cot et al. Dual HIV-1 and HIV-2 infection in West Africa supported by synthetic peptide analysis
Vallari et al. Rapid assay for simultaneous detection and differentiation of immunoglobulin G antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2
Montagnier Origin and evolution of HIVs and their role in AIDS pathogenesis
Barrett et al. Performance evaluation of the Abbott HTLV III EIA, a test for antibody to HTLV III in donor blood
Massanga et al. A highly heterogeneous HIV-1 epidemic in the Central African Republic.
Huisman et al. Detection of early anti-p24 HIV responses in EIA-and immunoblot-negative individuals
Delaporte et al. Interpretation of antibodies reacting solely with human retroviral core proteins in western equatorial Africa

Legal Events

Date Code Title Description
PUP Patent expired

Expiry date: 20250204